Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Defibrotide inhibits endothelial injury induced by plasmas of patients with TMA

Jeffrey Laurence • 7 Dec 2019
ASH 2019
General Defibrotide

Thrombotic microangiopathies (TMAs) complicate ~20% of alloHSCT procedures, and although half of cases may resolve when GvHD immunoprophylaxis is discontinued, 3-year survival rates for those in whom the TMA persists are poor. Here, Jeffrey Laurence, MD, Weill Cornell Medical College, Greenwich, CT, discusses the analysis of the effect of defibrotide on endothelial injury induced by plasmas of patients with TMAs. An inhibitory effect was observed, indicating that defibrotide may represent an important resource for the treatment of TMA, although Dr Laurance highlights how further studies are required. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Jeffrey Laurence

4:22
Are Masp-2 levels after allo-HSCT associated with TMA development?
Jeffrey Laurence • 7 Dec 2019

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals